Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023907 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00023907 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group.
The verdict
NCT00023907, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.
Interventions
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023907
The ClinicalTrials.gov registry entry for NCT00023907 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paclitaxel is the first listed.
NCT00023907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00023907 about?
NCT00023907 is a clinical study titled "Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.
What is the current status of trial NCT00023907?
This trial is currently terminated. It is a Phase 2 study. The study started on 2001-07.
What interventions are being tested in trial NCT00023907?
The interventions under investigation include: paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00023907?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.